Tumor burden analysis at 19 weeks after CMV-AdCre infection showed that constitutive loss of EphA3 did not alter mutant Kras-driven lung ADC progression (Fig. 1A,B; supplementary material Fig. S1C). This evidence concerns the gene KRAS and neoplasm.